ImmunityBio
  • Founder’s Vision
  • ANKTIVA®
  • BCG
  • Clinical Trials
    • Find a Trial
    • Become a Trial
      Investigator
    • License our Cells
  • Science
    • Platforms
    • Pipeline
    • Expanded Access
    • Research
  • Approach
    • Patients
    • Trial Investigators
    • Researchers
  • Condition
    • Bladder Cancer
    • Glioblastoma
    • HIV
    • Lynch / Colon Cancer
    • Non-Hodgkin Lymphoma
    • Ovarian Cancer
    • Human Papillomavirus
    • Non-Small Cell Lung Cancer
  • Company
    • About Us
    • News & Events
    • Careers
    • Investors
    • Contact
Select Page

The human IL-15 superagonist ALT-803 directs SIV-specific CD8(+) T cells into B-cell follicles.

Feb 12, 2018 | Uncategorized

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation.

Feb 12, 2018 | Uncategorized

ALT-803 Transiently Reduces Simian Immunodeficiency Virus Replication in the Absence of Antiretroviral Treatment.

Feb 1, 2018 | Uncategorized

Providing a Homing Receptor for CAR Engineered NK Cells – Improving Cellular Immunotherapy for B-Cell Lymphomas

Jan 28, 2018 | Uncategorized

CD16(+)NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice

Jan 28, 2018 | Uncategorized

« Older Entries
Next Entries »

Recent Posts

  • LUGPA Regional Meeting
  • ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer
  • ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors
  • Jefferies Global Healthcare Conference 2025
  • ImmunityBio, Saudi Arabia’s Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShieldTM Platform in the Middle East
 

Quicklinks

  • Pipeline
  • Careers
  • News and Events
  • Investors
  • Contact

Follow Us

  •  Facebook
  •  X
  •  LinkedIn

Legal

  • Privacy Policy
  • Legal Notice
  • Patent Notice
  • How-To-Use-Accessibe

© 2025 ImmunityBio, Inc. All Rights Reserved.

A member of the NantWorks ecosystem of companies

’ImmunityBio’, ‘ImmunityBio Care’, 'Anktiva’, ‘ThAnktiva’, ‘haNK’, ‘taNK’, ‘ceNK’, ‘NK-92’, ‘Nant Cancer Vaccine’, ‘NANT 001’, ‘NANT XL’, ‘NANT 001 and Design’, ‘QUILT’, ‘Outsmart Your Disease’, ‘Smart Therapies for Difficult Diseases’, ‘Nantkwest’, ‘VivaBioCell’, and ‘Infacell’ are trademarks or registered trademarks of ImmunityBio, Inc., its subsidiaries and affiliates.

The Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only.

The Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites.

The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.

Sitemap